Medigen Biotechnology Corporation (3176) Stock Price & Analysis
3176 Stock Chart & Stats
- Day’s Range
- $29.30 - $31.80
- 52-Week Range
- $28.50 - $43.60
- Previous Close
- $31.80
- Volume
- N/A
- Average Volume (3M)
- 310.58K
- Market Cap
- TWD 4.42B
- Enterprise Value
- TWD 6.91B
- Total Cash (Recent Filing)
- TWD 2.72B
- Total Debt (Recent Filing)
- TWD 1.72B
- Price to Earnings (P/E)
- ―
- Beta
- 0.40
- Next Earnings
- Nov 18, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
3176 FAQ
What was Medigen Biotechnology Corporation’s price range in the past 12 months?
What is Medigen Biotechnology Corporation’s market cap?
When is Medigen Biotechnology Corporation’s upcoming earnings report date?
How were Medigen Biotechnology Corporation’s earnings last quarter?
Is Medigen Biotechnology Corporation overvalued?
Does Medigen Biotechnology Corporation pay dividends?
What is Medigen Biotechnology Corporation’s EPS estimate?
How many shares outstanding does Medigen Biotechnology Corporation have?
What happened to Medigen Biotechnology Corporation’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Medigen Biotechnology Corporation?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Medigen Biotechnology Corporation
Medigen Biotechnology Corp. is a Taiwanese biopharmaceutical company dedicated to inventing therapies for liver diseases and various forms of cancer. Its product portfolio includes advanced cell therapies like MAGICELL-NK, which leverages natural killer cells, and MAGICELL-GDT, a T-cell-based treatment. A significant pipeline asset for Medigen is OBP-301. This therapeutic has completed Phase I clinical trials for combination therapy in esophageal cancer in Japan. It is currently being evaluated in ongoing Phase I trials in Japan, combining it with immune checkpoint inhibitors (ICIs) for esophageal cancer, and has advanced to Phase II studies in the United States, investigating its use with ICIs for both esophageal and gastric cancer. Established in 1999, Medigen Biotechnology Corp. maintains its corporate headquarters in Taipei, Taiwan.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Shi-Chung Chang
- Employees
- 67
- Website
- www.medigen.com.tw
- Address
- No.3, Park Street, Taipei, TPE, 115603, TW
Medigen Biotechnology Corporation (3176) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |

